Vote 2020 graphic
Everything you need to know about and expect during
the most important election of our lifetimes

Increased Access to Plan B Does Nothing for Drug Companies' Profits

Illustration for article titled Increased Access to Plan B Does Nothing for Drug Companies Profits

Now that the Obama administration has dropped its appeal to keep age restrictions on sales of emergency contraception, it means the aisles of CVS will witness stampedes of wanton sluts eager to get their hussy hands on whore pills while evil drug companies are maniacally laughing as they roll around in a pile of cash like Demi Moore in Indecent Proposal, right? No.

Advertisement

It turns out that the lifted restrictions—whereby women and girls of all ages can purchase the morning after pill without a prescription or the embarrassing task of having to ask for it at the pharmacy counter—will have little impact on the botom lines of the companies that make emergency contraception.

Advertisement

Take Teva Pharmaceuticals Industries for example. In the last year, over-the-counter sales of Plan B One-Step brought in $93 million. But to put those earnings in perspective, that's only 2% of what the company's top-selling drug earned — a multiple sclerosis treatment that did $4 billion in sales.

And it makes sense that Plan B isn't some kind of money faucet like say, Viagra, because Viagra is all about having fun without any consequences (kind of like what sex often is for men). And perhaps more than anything, men buy Viagra in the hope of getting laid, whereas women buy Plan B in the despair that occasionally follows doing so.

So while all of these political battles and moral debates have been waged over the access of emergency contraception in the last decade, with people concerned that making the drug available to young girls will encourage sexual activity, they seemed to ignore the fact that Plan B is a major bummer that nobody actually wants. It's something that the drug companies are more than aware of, according to the New York Times:

Indeed, the news barely budged Teva’s stock, which closed down 0.42 percent Tuesday, to $39.83. Some industry analysts said the drug was simply not on their radar and was rarely discussed during earnings calls or in company presentations.

Advertisement

So the lift on the restrictions earlier this week wasn't so much of a windfall for big corporations, but a genuine victory for women.

Lifting Restrictions of ‘Morning After’ Pill Has Little Impact for Drug Maker [NYT]

Share This Story

Get our newsletter

DISCUSSION

leggomypoptarr
leggomypoptarr

This legalization is indeed a good thing for women, but I don't understand why we are trying to argue that Teva won't profit from it? Of course they will. Increased access, barring some kind of scandal, will yield increased sales and you've supplied no hard facts to indicate otherwise. It may not be expected to be a huge money maker but why pretend like the company that produces it doesn't stand to profit from minors having access?

My mother happens to be on the multiple sclerosis medication that Tracie mentioned and it is a several-thousand-dollar-a-month subscription service that patients are essentially on for life. Its a drug that has been on the market for a while now and has plateaued in terms of its profitability. So these medications are apples and oranges... to even bring it into this conversation shows a profound lack of medical knowledge and prior research.